Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Mühlberg

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Drug Discovery Today|November 3, 2025
Exploiting the unique properties of nanobodies: enhancing therapeutics, drug delivery, and targeted diagnosticsLisa Blank, Giulia Pander, Eric Mühlberg, et al.
Canadian Journal of Microbiology|September 24, 2019
Renaissance of vancomycin: approaches for breaking antibiotic resistance in multidrug-resistant bacteriaEric Mühlberg, Florian Umstätter, Christian Kleist, et al.
Nanomedicine (London, England)|July 16, 2021
Trends in liposomal nanocarrier strategies for the oral delivery of biologicsEric Mühlberg, Mira Burtscher, Florian Umstätter, et al.
Pharmaceuticals (Basel, Switzerland)|June 4, 2020
Vancomycin-Lipopeptide Conjugates with High Antimicrobial Activity on Vancomycin-Resistant EnterococciEric Mühlberg, Florian Umstätter, Cornelius Domhan, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|December 29, 2023
Improved pharmacokinetics and enhanced efficacy of the vancomycin derivative FU002 using a liposomal nanocarrierJulia Werner, Florian Umstätter, Tobias Hertlein, et al.
Advanced Healthcare Materials|February 22, 2024
Oral Delivery of the Vancomycin Derivative FU002 by a Surface-Modified Liposomal NanocarrierJulia Werner, Florian Umstätter, Tobias Hertlein, et al.
Angewandte Chemie (International Ed. in English)|March 20, 2020
Vancomycin Resistance Is Overcome by Conjugation of Polycationic PeptidesFlorian Umstätter, Cornelius Domhan, Tobias Hertlein, et al.
Pharmaceuticals (Basel, Switzerland)|February 26, 2022
Impact of Linker Modification and PEGylation of Vancomycin Conjugates on Structure-Activity Relationships and PharmacokineticsFlorian Umstätter, Julia Werner, Leah Zerlin, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|May 11, 2026
Balancing Stealth and Targetability: cCPP- and PEG-Modified Liposomes for the Targeted Delivery of Anti-HER2 NanobodiesGiulia Pander, Maria Del Pilar Palacios Cisneros, Clara Certa, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 4, 2025
Brain delivery of a neurotrophic peptide derived from secreted amyloid precursor protein APPsα as a therapeutic strategy for Alzheimer's diseaseLena Rehra, Susanne Erdinger, Lelia Wagner, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Drug Discovery Today|November 3, 2025
Exploiting the unique properties of nanobodies: enhancing therapeutics, drug delivery, and targeted diagnosticsLisa Blank, Giulia Pander, Eric Mühlberg, et al.
Canadian Journal of Microbiology|September 24, 2019
Renaissance of vancomycin: approaches for breaking antibiotic resistance in multidrug-resistant bacteriaEric Mühlberg, Florian Umstätter, Christian Kleist, et al.
Nanomedicine (London, England)|July 16, 2021
Trends in liposomal nanocarrier strategies for the oral delivery of biologicsEric Mühlberg, Mira Burtscher, Florian Umstätter, et al.
Pharmaceuticals (Basel, Switzerland)|June 4, 2020
Vancomycin-Lipopeptide Conjugates with High Antimicrobial Activity on Vancomycin-Resistant EnterococciEric Mühlberg, Florian Umstätter, Cornelius Domhan, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|December 29, 2023
Improved pharmacokinetics and enhanced efficacy of the vancomycin derivative FU002 using a liposomal nanocarrierJulia Werner, Florian Umstätter, Tobias Hertlein, et al.
Advanced Healthcare Materials|February 22, 2024
Oral Delivery of the Vancomycin Derivative FU002 by a Surface-Modified Liposomal NanocarrierJulia Werner, Florian Umstätter, Tobias Hertlein, et al.
Angewandte Chemie (International Ed. in English)|March 20, 2020
Vancomycin Resistance Is Overcome by Conjugation of Polycationic PeptidesFlorian Umstätter, Cornelius Domhan, Tobias Hertlein, et al.
Pharmaceuticals (Basel, Switzerland)|February 26, 2022
Impact of Linker Modification and PEGylation of Vancomycin Conjugates on Structure-Activity Relationships and PharmacokineticsFlorian Umstätter, Julia Werner, Leah Zerlin, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|May 11, 2026
Balancing Stealth and Targetability: cCPP- and PEG-Modified Liposomes for the Targeted Delivery of Anti-HER2 NanobodiesGiulia Pander, Maria Del Pilar Palacios Cisneros, Clara Certa, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 4, 2025
Brain delivery of a neurotrophic peptide derived from secreted amyloid precursor protein APPsα as a therapeutic strategy for Alzheimer's diseaseLena Rehra, Susanne Erdinger, Lelia Wagner, et al.
Pageof 2